Article info
Original research
Cytokeratin 18 cell death assays as biomarkers for quantification of apoptosis and necrosis in COVID-19: a prospective, observational study
- Correspondence to Dr Brandon Michael Henry, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA; Brandon.henry{at}cchmc.org
Citation
Cytokeratin 18 cell death assays as biomarkers for quantification of apoptosis and necrosis in COVID-19: a prospective, observational study
Publication history
- Received November 8, 2020
- Revised February 21, 2021
- Accepted February 24, 2021
- First published March 31, 2021.
Online issue publication
May 19, 2022
Article Versions
- Previous version (31 March 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage